Research finds high MYC activity in pancreatic cancer cells enhances DNA repair and resistance — Evidence Review
Published in Genes & Development, by researchers from Oregon Health & Science University, University of Würzburg
Researched by
— the AI search engine for science
Table of Contents
Scientists at Oregon Health & Science University report that the cancer-linked protein MYC not only drives tumor growth but also directly aids DNA repair in cancer cells, potentially making tumors more resistant to chemotherapy. Related research generally supports the idea that MYC contributes to treatment resistance in cancer by influencing DNA repair and cell survival, as discussed in The Scientist article.
- Multiple studies have found that MYC enhances chemotherapy resistance by regulating processes such as mitochondrial function, cancer stem cell maintenance, and DNA repair, aligning with the new finding that MYC activity confers survival advantages to cancer cells under therapeutic stress 1 5 12.
- Existing research indicates that targeting DNA repair pathways—including those influenced by MYC—can sensitize tumor cells to chemotherapy or radiation, underscoring the potential of MYC as a therapeutic target 6 7 10.
- Some studies highlight the complexity of MYC's role, noting that its impact on chemotherapy outcomes may vary by cancer type and cellular context, with both treatment sensitivity and resistance observed depending on the tumor model and MYC regulation 2 13 14.
Study Overview and Key Findings
Understanding why certain cancers resist chemotherapy is a critical challenge in oncology. This study focuses on the MYC protein, a well-known oncogene, revealing a previously underappreciated role in directly facilitating DNA repair in cancer cells. The research is particularly relevant for aggressive cancers such as pancreatic cancer, where MYC is highly active and patient outcomes are typically poor.
The study demonstrates that a modified form of MYC relocates to sites of DNA damage and recruits repair proteins, helping cancer cells survive DNA-damaging therapies. These findings build on decades of work on MYC but add important new insights into how this protein may contribute to treatment resistance.
| Property | Value |
|---|---|
| Organization | Oregon Health & Science University, University of Würzburg |
| Journal Name | Genes & Development |
| Authors | Rosalie Sears, Gabriel Cohn |
| Population | Pancreatic cancer cells derived from patients |
| Outcome | DNA repair activity and treatment resistance |
| Results | Cancers with high MYC activity showed increased DNA repair and worse outcomes. |
Literature Review: Related Studies
To place these findings into context, we searched the Consensus paper database, which indexes over 200 million research papers. The following queries were used to identify relevant studies:
- MYC activity cancer chemotherapy resistance
- DNA repair mechanisms in cancer survival
- chemotherapy outcomes high MYC expression
Below is a synthesis of the main themes and findings from the related research:
| Topic | Key Findings |
|---|---|
| How does MYC contribute to chemotherapy resistance? | - MYC supports chemotherapy resistance by promoting cancer stem cell survival, metabolic adaptation, and overcoming DNA damage 1 5 12. - MYC-driven cancers can resist therapy by rapidly repairing DNA or adopting dormant states under stress 2 13. |
| What is the relationship between DNA repair mechanisms and cancer therapy outcomes? | - Enhanced DNA repair capacity in tumor cells can lead to resistance to chemotherapy and radiotherapy, making DNA repair pathways attractive therapeutic targets 6 7 8 9 10. - Targeting DNA damage response pathways improves the effectiveness of existing therapies 10. |
| Does high MYC expression always predict poor treatment outcomes? | - High MYC expression is often linked to poor outcomes and resistance, but some studies report context-dependent effects, including cases where high MYC correlates with better response in specific cancers 13 14 15. |
| Can targeting MYC or its pathways improve cancer therapy? | - Inhibiting MYC directly or its synthetic lethal partners can sensitize cancer cells to chemotherapy and block resistance mechanisms 3 4 11. - Combination therapies targeting MYC-regulated pathways show promise in preclinical models 3 4. |
How does MYC contribute to chemotherapy resistance?
The new study highlights MYC's role in DNA repair as a mechanism for chemotherapy resistance, aligning with prior research identifying MYC as a central player in multiple resistance pathways. MYC not only enhances cancer cell proliferation but also supports survival by maintaining cancer stem cells and promoting metabolic reprogramming, both of which facilitate resistance to DNA-damaging therapies.
- MYC and MCL1 together boost oxidative phosphorylation, supporting the survival of chemotherapy-resistant cancer stem cells 1.
- MYC overexpression in breast and colorectal cancer models is associated with increased resistance to standard chemotherapeutics 1 5 12.
- Some tumor cells can enter a dormancy-like state with suppressed MYC activity to survive treatment, indicating that both MYC upregulation and downregulation can contribute to persistence, depending on the context 2.
- High-MYC cells may bypass cell-cycle checkpoints and repair DNA damage more efficiently, enabling regrowth after chemotherapy 13.
What is the relationship between DNA repair mechanisms and cancer therapy outcomes?
The ability of cancer cells to efficiently repair DNA damage is a major factor underlying treatment resistance. The new findings that MYC directly aids DNA repair reinforce the importance of DNA repair pathways as both a challenge and an opportunity in cancer therapy.
- Inhibitors targeting specific DNA repair pathways can enhance the cytotoxic effects of chemotherapy in tumors with high repair capacity 6 7.
- The DNA damage response (DDR) is a recognized vulnerability in cancer cells, with ongoing research into exploiting these weaknesses for therapeutic benefit 7 8 9.
- Synthetic lethal approaches, such as PARP inhibition in BRCA-mutant tumors, exemplify successful targeting of DNA repair dependencies 10.
- Understanding and targeting DDR is central to improving cancer treatment, as tumors often rely on a limited set of repair mechanisms due to genomic instability 9 10.
Does high MYC expression always predict poor treatment outcomes?
While high MYC activity is frequently associated with resistance and poor prognosis, the relationship is complex and context-dependent. Some evidence suggests that MYC's impact can vary by tumor type, therapeutic context, and co-occurring molecular features.
- In ovarian cancer, higher c-myc expression was linked to better chemotherapy response and improved survival, highlighting a nuanced relationship 14.
- MYC-driven tumor cells can sometimes be more susceptible to specific drug combinations or targeted therapies, particularly when synthetic lethal interactions are exploited 3 11.
- The cell-cycle position and MYC expression level at the time of treatment can influence whether a cancer cell survives or undergoes therapy-induced senescence 13.
- In some breast cancer contexts, MYC expression did not impact the benefit derived from targeted therapy (trastuzumab) 15.
Can targeting MYC or its pathways improve cancer therapy?
Given MYC's central role in both tumor growth and therapy resistance, considerable interest exists in developing strategies to inhibit MYC or its downstream effectors. The new study's focus on MYC's DNA repair function may open new therapeutic avenues.
- Direct inhibition of MYC has been challenging, but targeting its synthetic lethal partners (e.g., IRE1/XBP1, Aurora Kinase) or pathways it regulates (e.g., metabolism, DNA repair) has shown efficacy in preclinical models 3 4 11.
- Combination therapies that suppress MYC activity or exploit vulnerabilities in MYC-driven tumors can delay or overcome resistance 3 4.
- The context-specific nature of MYC's role highlights the need for personalized approaches, potentially guided by biomarkers of MYC activity and DNA repair capacity 11 13.
- Ongoing clinical trials are exploring first-in-class MYC inhibitors and their impact on tumor biology and patient outcomes, as noted in the new study.
Future Research Questions
Further research is needed to clarify how MYC's role in DNA repair can be targeted safely and effectively, and to explore the broader implications for therapy resistance and patient stratification. The following questions emerge from this work:
| Research Question | Relevance |
|---|---|
| How can MYC's non-canonical DNA repair function be specifically targeted in cancer therapy? | Understanding this could lead to more precise interventions that selectively disrupt tumor survival mechanisms without affecting normal cell functions 3 4 6 11. |
| What biomarkers predict which tumors are most dependent on MYC-mediated DNA repair? | Identifying predictive biomarkers would enable better patient stratification and targeted therapy, maximizing benefit and minimizing toxicity 7 10 11. |
| Can combination therapies that target MYC and DNA repair pathways overcome treatment resistance? | Exploring combinations could address the challenge of resistance and improve outcomes in aggressive cancers with high MYC activity 1 3 4 7 10. |
| How does MYC-mediated DNA repair differ across cancer types and treatment contexts? | The relationship between MYC and treatment response is context-dependent; understanding these differences could inform more tailored therapeutic approaches 2 13 14 15. |
| What are the long-term effects of MYC inhibition on normal tissue function and tumor recurrence? | MYC is essential for normal cellular processes; assessing safety and long-term outcomes is critical for translating MYC-targeted therapies into clinical practice 6 10. |